Earnings Feed
Start Free
Keros Therapeutics, Inc.·4

Jun 5, 4:15 PM ET

Farzan Nima 4

Research Summary

AI-generated summary

Updated

Keros Therapeutics (KROS) Director Farzan Nima Receives RSUs and Option Award

What Happened
Farzan Nima, a director of Keros Therapeutics (KROS), received two equity awards on June 3, 2026: 7,142 restricted stock units (RSUs) and a 7,433-share derivative award. Both were reported as grants (transaction code A) at $0.00 per share (total $0 as reported on the Form 4). These are compensation awards, not open-market purchases or sales.

Key Details

  • Transaction date: 2026-06-03; Form 4 filed 2026-06-05 (timely — within the 2-business-day window).
  • Awards granted: 7,142 RSUs + 7,433 derivative shares = 14,575 total units; reported acquisition price $0.00.
  • Vesting (from filing footnotes):
    • RSUs (F1) vest on the earlier of June 3, 2027 or the issuer’s 2027 annual meeting, subject to continued service.
    • Derivative award (F2) vests in equal quarterly installments over the 12 months after June 3, 2026, but in any case will be fully vested at the 2027 annual meeting, subject to continued service.
  • Shares owned after the transaction: not specified in the provided filing excerpt.
  • No exercise or sale occurred; these are grants that will convert to stock only upon vesting.

Context
RSU and option-style grants to directors are common compensation practices and reflect deferred pay that vests with continued service rather than immediate insider buying. The derivative award here appears to be an option-like grant with time-based vesting; no cashless exercise or immediate dispositions were reported.